BMO Capital analyst Evan Seigerman has maintained their bullish stance on REPL stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Evan Seigerman’s rating is based on Replimune Group’s promising developments and strong financial position. The company’s recent Biologics License Application (BLA) submission for RP1 in advanced melanoma indicates a potential FDA approval in the near future, which is anticipated to be a significant milestone for Replimune by potentially receiving its first approval before the end of 2025. This approval could enable early sales and solidify the company’s presence in the oncology market.
Furthermore, Replimune’s initiation of clinical trials for RP2 in uveal melanoma and hepatocellular carcinoma (HCC) reflects the company’s ongoing commitment to expanding its pipeline. The strong cash position of approximately $537 million is expected to support the commercialization of RP1 and further research and development activities for RP2. These factors collectively contribute to Seigerman’s optimistic outlook on Replimune’s growth potential, leading to his Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $17.00 price target.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REPL in relation to earlier this year.